| Nome |
# |
|
Implementation of value-based pricing for medicines, file e31e10d3-f045-31fb-e053-1705fe0a5b99
|
1.199
|
|
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi, file e31e10d3-a840-31fb-e053-1705fe0a5b99
|
201
|
|
CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions, file 52b450c3-4e8b-4219-a875-3f6985776264
|
193
|
|
Esiti di salute e performance del Servizio Sanitario Nazionale, file a7982d94-7008-4faf-b82c-ee0c5acb90bd
|
149
|
|
Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates, file e31e10d3-a7be-31fb-e053-1705fe0a5b99
|
119
|
|
Patient access to oral nutritional supplements: which policies count?, file e31e10d3-aeca-31fb-e053-1705fe0a5b99
|
102
|
|
Tempi di accesso ai farmaci in Italia nel periodo 2015-2017: analisi delle tempistiche di valutazione dell’Agenzia Italiana del Farmaco, file e31e10d3-af27-31fb-e053-1705fe0a5b99
|
100
|
|
Second-generation antipsychotic drugs for patients with schizophrenia: systematic literature review and meta-analysis of metabolic and cardiovascular side effects, file e31e10d4-437b-31fb-e053-1705fe0a5b99
|
98
|
|
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci, file e31e10d2-fcc9-31fb-e053-1705fe0a5b99
|
94
|
|
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento, file e31e10d3-0735-31fb-e053-1705fe0a5b99
|
93
|
|
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system, file e31e10d4-7987-31fb-e053-1705fe0a5b99
|
70
|
|
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study, file e31e10d3-afd9-31fb-e053-1705fe0a5b99
|
65
|
|
The future of Funds for Innovative Medicines: results from a Delphi Study, file e31e10d4-60f9-31fb-e053-1705fe0a5b99
|
65
|
|
Next-Generation Sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach?, file e31e10d4-5cef-31fb-e053-1705fe0a5b99
|
63
|
|
Health care costs of influenza-related episodes in high income countries: a systematic review, file e31e10d3-a7b9-31fb-e053-1705fe0a5b99
|
62
|
|
The economic impact of a switch from prescription-only to non-prescription drugs in Italy, file e31e10d3-ac3c-31fb-e053-1705fe0a5b99
|
58
|
|
The effects of disease cross-coverage by dupilumab on the costs sustained by the Italian National Health Service, file e31e10d4-5ce1-31fb-e053-1705fe0a5b99
|
51
|
|
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration, file e31e10d4-75eb-31fb-e053-1705fe0a5b99
|
46
|
|
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol, file e31e10d3-f049-31fb-e053-1705fe0a5b99
|
42
|
|
EQ-5D-5L population norms for Italy, file f4b347a1-e27b-4530-9dbb-da683dc4a07a
|
37
|
|
Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital, file e31e10d4-60fd-31fb-e053-1705fe0a5b99
|
36
|
|
The economic impact of compassionate use of medicines, file e31e10d4-7985-31fb-e053-1705fe0a5b99
|
32
|
|
Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals, file e31e10d4-018f-31fb-e053-1705fe0a5b99
|
31
|
|
Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system, file e31e10d4-60f7-31fb-e053-1705fe0a5b99
|
31
|
|
Facilitating more efficient negotiations for innovative therapies: a value-based negotiation framework, file e31e10d4-9718-31fb-e053-1705fe0a5b99
|
30
|
|
Variables affecting pricing of orphan drugs: the Italian case, file e31e10d4-9b7c-31fb-e053-1705fe0a5b99
|
27
|
|
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?, file e31e10d4-60f0-31fb-e053-1705fe0a5b99
|
22
|
|
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service, file e31e10d3-e3f3-31fb-e053-1705fe0a5b99
|
12
|
|
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?, file 156bfc50-3f5b-4651-914a-a5d0ae381865
|
11
|
|
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case, file 74e9fba6-acc1-4e61-80ca-ba5cc97a5b6e
|
11
|
|
Stakeholders involvement by HTA Organisations: Why is so different?, file e31e10d2-22c9-31fb-e053-1705fe0a5b99
|
10
|
|
Il processo decisionale negli Istituti di Health Technology Assessment, file e31e10d2-22cb-31fb-e053-1705fe0a5b99
|
10
|
|
New funding arrangements in the Italian National Health Service, file e31e10d2-216e-31fb-e053-1705fe0a5b99
|
9
|
|
La raccolta di plasma e il sistema di emocomponenti ed emoderivati in Italia, file e31e10d2-313f-31fb-e053-1705fe0a5b99
|
5
|
|
I registri in sanità e la creazione di conoscenza: dai database alla produzione scientifica, file e31e10d2-4dc5-31fb-e053-1705fe0a5b99
|
5
|
|
Report n. 42 OSFAR (Osservatorio Farmaci), file 5c55be94-59c7-4640-8c57-75da4ddee62a
|
4
|
|
Patients’ associations and HTA for medicines: actual and future role in Italy, file e31e10d3-558c-31fb-e053-1705fe0a5b99
|
4
|
|
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement), file e31e10d4-9b7f-31fb-e053-1705fe0a5b99
|
4
|
|
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study, file 8437773d-f25c-46d0-b947-9c7357a5a133
|
3
|
|
Phasing out market mechanisms in the Italian National Health Service, file e31e10d2-1a4b-31fb-e053-1705fe0a5b99
|
3
|
|
La ricerca clinica in nove ospedali italiani: organizzazione e analisi di percezione, file e31e10d2-332f-31fb-e053-1705fe0a5b99
|
3
|
|
Managed entry agreements and high cost medicines (European perspective), file e31e10d3-ac8c-31fb-e053-1705fe0a5b99
|
3
|
|
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service, file e31e10d4-3d6c-31fb-e053-1705fe0a5b99
|
3
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-20ab-31fb-e053-1705fe0a5b99
|
2
|
|
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa, file e31e10d2-246e-31fb-e053-1705fe0a5b99
|
2
|
|
Diagnostic accuracy of HLA-B*5701 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review, file e31e10d2-2f3c-31fb-e053-1705fe0a5b99
|
2
|
|
Towards a more competitive Italy in clinical research: the survey of attitudes towards trial sites in Europe (the SAT-EU study™), file e31e10d2-534a-31fb-e053-1705fe0a5b99
|
2
|
|
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making, file e31e10d2-564c-31fb-e053-1705fe0a5b99
|
2
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-58a4-31fb-e053-1705fe0a5b99
|
2
|
|
The impact of HTA and procurement practices on the selection and prices of medical devices, file e31e10d2-9f15-31fb-e053-1705fe0a5b99
|
2
|
|
La gestione della ricerca clinica. Evidenze dalla letteratura scientifica sulle Clinical Trial Unit e dall’indagine di percezione condotta in alcune realtà italiane, file e31e10d2-a5fa-31fb-e053-1705fe0a5b99
|
2
|
|
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane, file e31e10d2-d040-31fb-e053-1705fe0a5b99
|
2
|
|
Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives, file e31e10d3-428b-31fb-e053-1705fe0a5b99
|
2
|
|
Quanto vale la negoziazione del prezzo di un nuovo farmaco in Italia?, file e31e10d3-e604-31fb-e053-1705fe0a5b99
|
2
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-20a9-31fb-e053-1705fe0a5b99
|
1
|
|
Market access management by pharmaceutical companies in a complex environment: the Italian case study, file e31e10d2-22cd-31fb-e053-1705fe0a5b99
|
1
|
|
L'attività sperimentale sui dispositivi medici, file e31e10d2-22d2-31fb-e053-1705fe0a5b99
|
1
|
|
L'attività sperimentale sui dispositivi medici, file e31e10d2-22d3-31fb-e053-1705fe0a5b99
|
1
|
|
La gestione dell'innovazione tecnologica in sanità: analisi e confronto di alcune politiche regionali in Italia, file e31e10d2-23cc-31fb-e053-1705fe0a5b99
|
1
|
|
Il value based pricing: opportunità e rischi, file e31e10d2-2e4d-31fb-e053-1705fe0a5b99
|
1
|
|
La raccolta di plasma e il sistema di emocomponenti ed emoderivati in Italia, file e31e10d2-313e-31fb-e053-1705fe0a5b99
|
1
|
|
Managed entry agreements and high cost medicines (European perspective), file e31e10d3-ac8d-31fb-e053-1705fe0a5b99
|
1
|
|
Clinical management of chronic Kidney disease patients in Italy: results from the IRIDE study, file e31e10d3-ac91-31fb-e053-1705fe0a5b99
|
1
|
|
Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency, file e31e10d3-aed1-31fb-e053-1705fe0a5b99
|
1
|
|
Prezzo, rimborso e accesso ai farmaci in Italia: le proposte di riforma di quattro panel di esperti, file e31e10d3-ed83-31fb-e053-1705fe0a5b99
|
1
|
| Totale |
3.249 |